Targeted irradiation of the bone marrow using radiolabeled monoclonal antibodies This pilot study demonstrates that RIT is effective in achieving myeloablation with low additional toxicity when used in combination with standard or reduced intensity conditioning in young patients.
β particle emitter, and more recently with 90 Y, which is a pure β particle emitter. In these studies, with patients suffering from high risk acute leukemia or myelodysplatic syndrome, RIT was mainly combined with high dose TBI or busulfan based conditioning regimens. [20] [21] [22] In one study, RIT was used as part of a dose-reduced, fludarabine containing conditioning for patients over the age of 55 years. 23 Relapse rates between 20% and 55% and non-relapse mortalities between 20% and 59% have been observed in these adult patients, resulting in leukemia free survival rates between 20% and 60%. [20] [21] [22] [23] [24] [25] Based on these encouraging results, we used RIT with 90 Y-anti-CD66 for conditioning in 30 pediatric and adolescent patients undergoing HCT. The aim was to evaluate the usefulness and applicability of RIT in this age group, when applied together with standard conditioning in patients at high risk of relapse as well as together with reduced intensity conditioning in patients with high co-morbidity. This is the first report on a series of younger patients with malignant and with non-malignant disease treated by this approach.
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Drug administration and preparative regimen prior to HCT
Details of the biology and the principles of the administration of radio-labeled monoclonal antibodies have been described previously. 23, 27 The anti-CD66 antibody (anti- Y activity was calculated based on the serial total-body gamma-camera counts 32 using adequate phantoms provided by the OLINDA/EXM software 33 to deliver a dose to the bone marrow of 30-35 Gy in patients in CR and 35 to 40 Gy in patients not in CR in the malignant group and 16-20 Gy in the non-malignant group. In addition, dose to the liver and to the kidneys had to be less than 12 Gy and 6 Gy, respectively (details of dosimetry are described in the supplemental information).
Step 1 and 2 were commonly performed on an outpatient basis. In step 3, patients underwent additional conditioning ( Twenty-one patients with high comorbidity and either malignant (n=5, A-9 to A14) or nonmalignant (n=15) diseases were treated with melphalan (70-140 mg/m²) and fludarabine (160 mg/m²) in addition to RIT. Two patients (B-8, B13) received melphalan (140 mg/m²) only or nothing else in addition to RIT prior to secondary transplantation after autologous reconstitution following first transplantation. To prevent graft rejection patients with HLA-mismatched donors or unrelated donors received antithymocyte globulin, either ATG Fresenius (Fresenius Biotec, Gräfelfing, Germany) at 50-60 mg/kg or thymoglobuline (Genzyme GmbH, Neu Isenburg, Germany) at 10 mg/kg (see Table 2 for details of conditioning). HCT was performed 14 days after infusion of the radiolabeled antibody (step 2) to avoid relevant irradiation of the graft.
Transplantation, GvHD prophylaxis and supportive care
Details of donors and stem cell sources are depicted in Table 2 . MSD and MFD are genotypically HLA-identical, MUD are defined as identical in HLA-A, -B, -C, -DRB1, and -DQB1 loci by high resolution genetic typing. Mismatched donors comprised one unrelated donor with a single locus mismatch and 5 HLA-haplodentical family donors.
Grafts were G-CSF-mobilized peripheral blood stem cells (PBSC) in 11 patients and bone marrow (BM) in 19 patients.
T-cell depleted PBSC were prepared by CD34+ selection using the immunomagnetic CliniMACS device (Milteny Biotec, Bergisch Gladbach, Germany) . 34, 35 In HLAhaploidentical transplants, the targeted dose of T-cells was less than 3 x 10 4 CD3+ cells /kg. In 4 transplants from matched unrelated donors, the T-cell dose was adjusted to 1 x 10 7 CD3+ cells /kg by T-cell add-backs. T-cell depletion was the sole GvHD prophylaxis in all 4 HLA-haploidentical transplants. In patients receiving grafts from matched unrelated donors, cyclosporine A and methotrexate or cyclosporine A and mycophenolate mofetil were given as GvHD prophylaxis. In patients receiving matched 
Results

Dosage and organ distribution of radioimmunotherapy
Mean therapeutic indices, i.e., the ratio of absorbed doses to bone marrow versus other organs, were 5.0 for the liver (range 1.1 to 10.0), 13.3 for the kidneys (range 2.2 to 46.1) and 85.4 for the lungs (range 6.2 to 347.0), respectively ( Figure 2 ). In all but three patients absorbed doses delivered by 90 Y-anti-CD66 RIT to the BM were more than two times higher compared to doses delivered to other organs except to the spleen. A preferential irradiation of the bone marrow with absorbed doses ranging from 11 Gy to 46 Gy in malignant diseases and from 16 Gy to 20 Gy in non-malignant diseases was achieved. The envisaged BM dose as described in the Methods section was reached in all but three patients. In these three patients with malignant diseases (A-3, A-9 and A-14) the BM dose was reduced in order not to exceed the maximum tolerated dose to the liver. In one patient (A-8) a BM dose of 46 Gy, which was applied accidentally, was tolerated without side effects. The estimated absorbed doses in bone marrow, spleen, liver, kidney and lung are shown in Figure S1 of the data supplement. All but two patients achieved stable primary engraftment. Time-to-engraftment was delayed in some patients with malignant diseases and in some patients receiving a cumulative radiation dose to the bone marrow of more than 20 Gy (for details see Table   S1 , Figure S2 and Figure S3 of the Supplemental Information). However, there was no significant difference of mean time to engraftment comparing TBI versus no TBI conditioning and comparing cumulative radiation dose of more or less than 40 Gy (see Table S1 of the Supplemental Information). Two patients rejected their primary haploidentical grafts: patient A-8 received a successful second transplant from the other parent after re-conditioning; patient B-3 died after repeat transplants from adenovirus pneumonia. The median time to achieve > 0.5 x 10 9 /L neutrophils was 22 days (range 
12-32 days) in patients of
Complications related to toxicity, infection, and GvHD
There were no immediate side effects and no acute toxicity related to the infusion of the radio-labeled antibodies and the procedure was well tolerated.
Major complications after transplantation are shown in Table 2 For
Discussion
In this report we present a series of pediatric and adolescent patients suffering from malignant or non-malignant disease treated with RIT in the context of HCT using a 90 Ylabeled anti-CD66 monoclonal antibody. The aim of the study was to explore the feasibility and tolerability of this approach in young patients with high risk factors for standard transplant procedures (advanced disease, high relapse risk and/or major pretransplant complications). We are fully aware of the fact that the limited number and the highly heterogeneous nature of the patients treated in this pilot study limit our ability to draw definitive conclusions from our findings. The three major findings of our study are:
1. RIT is feasible in young children and adolescents. The target dose to the marrow of 16-20 Gy was achieved in all patients with nonmalignant diseases with a highly favorable ratio of marrow dose to normal organ dose.
The maximal targeted absorbed dose to the marrow of 30 to 40 Gy in malignant diseases was reached in all but 3 cases. In these 3 cases the predefined maximum tolerated absorbed dose to the liver (12 Gy) was dose limiting. We observed no excess acute organ toxicity in any of the patient groups. In particular, no cases of radiation nephropathy or VOD were detected. This is in marked contrast to experience of Bunjes et al. 21 and Koeneke et al. 43 where radiation nephropathy and VOD were the dose limiting toxicities when using 188 Re as the therapeutic nuclide. 44, 45 This low organ toxicity is both remarkable and reassuring if one considers the fact that 22 of the 30 patients were considered to be at high risk for severe toxicity and this was the primary reason for including them in the study.
RIT appears not to have increased the incidence of other transplant-related complications such as GvHD or opportunistic infections. The good tolerability of RIT in the setting of myeloablative conditioning and RIC is best reflected in the NRM data. The overall NRM of 13% was considerably lower than predicted (28-53%) for standard conditioning by the Matthes-Martin risk scores of our cohort of patients. These data on
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All patients entered complete marrow aplasia. The median time to engraftment (neutrophils > 500/µl at day 18, platelets > 20 000/µl at day +44 for both groups) seems to be prolonged in comparison to conventional conditioning (see also Figure S2 A further major goal of this study was to evaluate the safety of selectively intensifying standard conditioning and RIC in patients with malignant diseases at very high risk of relapse after a conventional transplant. Our study demonstrates that RIT with our conjugate can be safely employed to target doses of 30-40 Gy to the marrow in children.
Because anti-leukemic efficacy was not the primary endpoint of this phase II study, only a few preliminary remarks with respect to this issue can be made. RIT appeared to be reasonably effective in reducing relapse in the subgroup of patients grafted with a low tumor burden at transplant similar to the experience of Bunjes et al. 21 This to some extent reflects the fact that RIT exerts its anti-leukemic effect by utilizing the crossfire effect and in the case of the anti-CD66 antibody this requires the presence of a large number of binding sites on normal granulopoietic cells in the marrow, i.e. a marrow in CR or very good PR. The same mechanisms explains why RIT with the anti-CD66 is unlikely to be effective at extramedullary sites, hence the significant incidence of extramedullary relapse in both our study and in the study by Bunjes et al. 21 Finally these data indicate that RIT at the marrow doses achieved in this study may be less effective in the RIC than in the myeloablative setting. A similar experience has been reported by Ringhoffer et al., 23 Koenecke et al. 43 and Lauter et al. 46 , using the 188 Re-labeled anti-CD66 antibody in adults.
In summary, RIT is a feasible therapeutic approach in children and adolescent, even in very young ones. Its short-term toxicity profile appears to be favorable. Further studies should be performed in the setting of both non-malignant and malignant diseases.
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